Source comparison
Melanotan-1 Research Review: Study Type Comparison
Phase III RCT (EPP) Erythropoietic protoporphyria photoprotection 16mg implant every 60 days Pain-free sun exposure duration (minutes) 69% increase vs placebo; FDA-approved indication with robust safety data Phase II Vitiligo Trial Autoimmune depigmentation 0.
This comparison does not assign a generated winner or score.
- Phase III RCT (EPP)
- Erythropoietic protoporphyria photoprotection
- 16mg implant every 60 days
- Pain-free sun exposure duration (minutes)
- 69% increase vs placebo; FDA-approved indication with robust safety data
- Phase II Vitiligo Trial
- Autoimmune depigmentation
- 0.16mg/kg SC every 48h for 12 weeks + NB-UVB
- Repigmentation percentage (chromameter L* value)
- 52% greater repigmentation vs phototherapy alone; limited to areas with residual melanocytes
- Healthy Volunteer Photoprotection
- Cosmetic tanning and UV defense
- 0.08–0.25mg/kg SC single dose or 6-dose series
- Minimal erythema dose (MED) shift and melanin index
- MED increased 2.8-fold after 6 doses at 0.16mg/kg; higher doses showed no additional benefit
- MC1R Binding Assay (In Vitro)
- Receptor pharmacology
- 10⁻⁹ to 10⁻⁵ M concentration range
- EC50 for cAMP production in MC1R-transfected cells
- EC50 ~2.3 nM; 40–60% potency loss if norleucine is oxidized or sequence contains substitutions